Led · Equity · Aug 2018

410 Medical develops advanced resuscitation technologies centered on its lead product, the LifeFlow infuser, which received FDA clearance in 2016. LifeFlow is used by more than 500 hospitals and EMS agencies and has been used to treat nearly 80,000 patients experiencing conditions like sepsis and hemorrhagic shock. The company was founded in 2013 and is based in North Carolina. In July 2026 410 Medical raised $12 million in growth financing led by Orlando Health Ventures to scale commercial operations and accelerate LifeFlow adoption. The company is also investing in a next-generation LifeFlow device planned for launch in 2027. The financing was supported by a syndicate of hospital and healthcare investors, reflecting continued commercial momentum.

Participated · Equity · Jun 2017

Synthio, formerly Social123 and based in Atlanta, is a customer data platform that automates the cleansing, standardization, and synthesis of contact, firmographic, and technographic data to make data actionable for marketers. Led by CEO and founder Aaron Biddar, the company serves mid-sized and enterprise customers worldwide through a subscription-based model and reports more than 200 active clients. The company raised $10.5M in financing to continue developing its platform and to expand its marketing, sales, and customer success teams. Prior to this round the company had raised $8M in earlier financings. The article does not disclose revenue figures or the specific financing instrument beyond 'financing.'

Participated · Equity · Apr 2017

Deep Fiber Solutions converts cable-operator coaxial cables to fiber optic infrastructure, enabling operators to deploy fiber deeper in the network. The company says this deployment is completed at substantially lower cost than traditional boring and trenching and in a fraction of the time. Pushing fiber deeper into the network results in dramatically lower power and maintenance costs. Deep Fiber Solutions offers a turnkey solution beginning with span qualification and ending with fiber splicing and activation of service over the new fiber optic network. The company is based in Roswell, GA. Deep Fiber Solutions recently completed an $8.9 million equity financing.

Participated · Equity · Jul 2014

OBMedical is developing LaborView, a wireless external electronic maternal-fetal monitoring sensor system intended as an alternative to traditional external sensors. LaborView technology uses neural networks, signal processing, information theory, data fusion, and artificial intelligence to improve monitoring. Clinical performance trials at University of Florida Health/Shands and Winnie Palmer Hospital produced highly satisfactory results. The company plans to use the new funding to complete safety, mechanical, and EMC testing, summative usability testing, and industrial design. Proceeds will support a 510(k) clearance filing, which was scheduled for the third quarter of 2014. Upon FDA clearance, LaborView is expected to work with all major brands of monitors in the U.S. and to offer more reliable, more comfortable, and more cost-effective obstetric monitoring with greater patient satisfaction. OBMedical develops LaborView™, a wireless, abdominal electrode-based electronic maternal-fetal monitor that measures labor contractions and maternal and fetal heart rates. LaborView was jointly developed by the University of Florida and Convergent Engineering and is designed to be compatible with legacy electronic fetal monitors. The company says its proprietary technology uses neural networks, signal processing, information theory, data fusion, and artificial intelligence informed by clinical experience at the University of Florida College of Medicine. LaborView is a Class II, non-significant risk device currently in performance clinical trials. OBMedical plans to complete those trials and file for 510(k) clearance, with design-for-manufacturing and industrial design work forthcoming. The company was founded in 2012 and is based in Gainesville (article header also lists Boca Raton).

Participated · Series A · Feb 2014

TNG Pharmaceuticals is a Louisville, KY–based animal pharmaceutical company developing FlyVax™, a patented vaccine intended to reduce damage from horn flies in cattle. FlyVax was first developed by research scientists at Auburn University and licensed by TNG, and has shown effectiveness in initial laboratory testing. The company completed a $4.6 million Series A Preferred Stock financing to fund completion of all phases of product development and move toward commercialization. TNG says the financing will allow it to commercialize the vaccine in a timely fashion. The company originated at the University of Louisville in the Entrepreneurship MBA program and was named the 2011 Global Business Plan Champion. Management positions the product as offering significant health and economic benefits for the cattle industry.